This is an international site for Exjade® (Deferasirox) and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country.

I am a healthcare professional I am a patient inside of the US I am a patient outside the U.S.

Home > Transfusion-Dependent β-Thalassemia > Efficacy > Severe Cardiac Iron Toxicity (T2* <10 ms)
Print

In this section:

Mild-Moderate Cardiac Iron Toxicity (T2* 10 to <20 ms) Severe Cardiac Iron Toxicity (T2* <10 ms) Preventing Cardiac Iron Loading (T2* >20 ms) EPIC 1-Year
Cardiac Substudy
EU SmPC
Severe Cardiac Iron Toxicity

Total Body Iron Chelation in Patients With
Severe Cardiac Iron Toxicity (T2* <10 ms)

T2* Improvements Above the 10-ms Severity Threshold in Patients With Severe Cardiac Iron Levels1
Severity Threshold

Learn more about the cardiac
substudy of the EPIC clinical trial.

  • Three-year results of the EPIC cardiac substudy myocardial siderosis (N=101). The investigators assessed the efficacy and safety of EXJADE in removing myocardial iron in heavily transfused patients with β-thalassemia1
  • T2* threshold of 10 ms was crossed by 3 years1
  • 50% of patients with severe cardiac iron severity had improved T2* to mild-moderate severity (T2* >10-<20 ms)1

Heavy iron burden is reduced by EXJADE at dosages up to 40 mg/kg/day2


Continued LIC and Serum Ferritin Reductions Over 3 Years (n=24)2
Continued LIC & Serum Ferritin Reductions Over 3 Years
  • In EPIC cardiac substudy, reductions in serum ferritin were observed from baseline through 3 years of treatment2
  • The recommended initial dose of EXJADE is 20 mg/kg/day3
  • Dosages of EXJADE up to 40 mg/kg/day provided potent serum ferritin reductions4
  • EXJADE is approved at doses up to 40 mg/kg/day for patients not adequately controlled with doses of 30 mg/kg (eg, serum ferritin levels persistently above 2,500 µg/L and not showing a decreasing trend over time)3
  • Doses above 40 mg/kg are not recommended because there is only limited experience with doses above this level3
More Information
Mild-Moderate Cardiac Iron Toxicity (T2* 10 to <20 ms) Severe Cardiac Iron Toxicity (T2* <10 ms) Preventing Cardiac Iron Loading (T2* >20 ms) EPIC 1-Year
Cardiac Substudy
EU SmPC

References

  1. Pennell DJ, Porter JB, Cappellini MD, et al. Continued improvement and normalization of myocardial T2* in patients with β-thalassemia major treated with deferasirox (EXJADE®) for up to 3 years. Abstract presented at: 52nd Annual Meeting of the American Society of Hematology; December 2010; Orlando, Florida.
  2. Pennell DJ, Porter JB, Cappellini MD, et al. Continued improvement and normalization of myocardial T2* in patients with β-thalassemia major treated with deferasirox (EXJADE®) for up to 3 years. Poster presented at: 52nd Annual Meeting of the American Society of Hematology; December 2010; Orlando, Florida.
  3. EXJADE® summary of product characteristics. West Sussex, United Kingdom: Novartis Europharm Limited; 2011.
  4. Cappellini MD, Porter J, El-Beshlawy A, et al. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica. 2010;95(4):557-566.
TRANSFUSION-DEPENDENT
β-THALASSEMIA		 MYELODYSPLASTIC SYNDROMES SICKLE CELL DISEASE APLASTIC AND OTHER ANEMIAS TOOLS AND RESOURCES ALL ABOUT EXJADE

EXJADE is indicated for the treatment of chronic iron overload due to frequent blood transfusions (≥ 7 ml/kg/month of packed red blood cells) in patients with beta thalassemia major aged 6 years and older.

EXJADE is also indicated for the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:

  • in patients with beta thalassemia major with iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) aged 2 to 5 years
  • in patients with beta thalassemia major with iron overload due to infrequent blood transfusions (<7 ml/kg/month of packed red blood cells) aged 2 years and older
  • in patients with other anemias aged 2 years and older
Disclaimer: This is an international website for Exjade, and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.
© Novartis AG | Use of this website is subject to our Terms of Use | About Novartis Oncology | Privacy | Site Map | Contact Us | EU SmPC | Safety Information | PubMed
Continued LIC and serum ferritin reductions over 3 years (n=24) Medium serum ferritin levels over 36 months Continued LIC and serum ferritin reductions over 3 years (n=24) Medium serum ferritin levels over 36 months